Newswise — DURHAM, N.C. – A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- New data were presented at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions from a study comparing ...
Januvia and Janumet are Merck & Co.'s (MRK) blockbuster diabetes drugs. They're used to lower blood sugar levels in patients with Type 2 diabetes. Combined sales for these drugs totaled ~$1.4 billion ...
(HealthDay)—Dextromethorphan combined with sitagliptin shows potential for treatment of type 2 diabetes mellitus, according to a study published online Sept. 12 in Diabetes, Obesity and Metabolism.
The DIVERSITY study arrives at a moment when clinicians increasingly recognize that the populations enrolled in randomized ...
"In this study, initial combination therapy with the fixed-dose combination JANUMET for the treatment of type 2 diabetes helped patients achieve blood sugar goals more effectively than metformin alone ...
Please provide your email address to receive an email when new articles are posted on . “Clinical practice guidelines recommend adding second-line agents, such as DPP-IV inhibitors, if glycemic ...
Januvia and Janumet are two blockbuster drugs in Merck & Co.'s (MRK) diabetes franchise. The drugs are used to lower the blood sugar level in patients with type-2 diabetes. The combined sales for ...
A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results